Literature DB >> 3019569

Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes.

L T Bich-Thuy, H C Lane, A S Fauci.   

Abstract

Human peripheral blood mononuclear cells as well as T-cell-enriched or T-cell-depleted populations were found to proliferate in response to recombinant interleukin-2 (IL-2) in vitro in the absence of a lectin preactivation signal. This proliferative response was detected at Day 2, peaked at Day 5, and was dependent on the concentration of IL-2 used. At the initiation of culture, these cells did not appear to be activated as determined by the expression of Tac antigens. In cultures of unfractionated T-cell-enriched suspensions, high concentrations of IL-2 resulted in preferential expansion of the OKT8+ population, although both OKT4+ and OKT8+ cells proliferated in response to IL-2 when cultured alone. These studies demonstrate that human lymphocytes obtained by standard fractionation procedures from peripheral blood are capable of proliferation in response to IL-2 without in vitro preactivation signals given by the addition of mitogens or antigens to cultures. These findings suggest that in vivo IL-2, in the absence of other exogenous stimuli, may directly influence immune responses and thus may have a potential role as a clinical immunopharmacologic agent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019569     DOI: 10.1016/0008-8749(86)90299-6

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  12 in total

1.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.

Authors:  J H Kehrl; M Dukovich; G Whalen; P Katz; A S Fauci; W C Greene
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

2.  Recombinant human interleukin-2-induced mitogenic proliferation of in vitro unstimulated bovine intestinal lymphocytes.

Authors:  A M Nagi; L A Babiuk
Journal:  Can J Vet Res       Date:  1989-01       Impact factor: 1.310

3.  Interleukin 2 receptor expression by human blood lymphocytes after vaccination with pneumococcal polysaccharides.

Authors:  N Tvede; C Heilmann; L D Christensen
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

4.  Lymphocytes expressing type 3 complement receptors proliferate in response to interleukin 2 and are the precursors of lymphokine-activated killer cells.

Authors:  J D Gray; D A Horwitz
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

5.  HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.

Authors:  R A Janssen; J Buter; E Straatsma; A A Heijn; D T Sleijfer; E G de Vries; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

6.  Lymphocyte responses to varicella zoster virus in the elderly.

Authors:  A R Hayward; M Herberger
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

7.  Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Ti gamma/delta or TNK phenotype.

Authors:  U Testa; A Care; E Montesoro; C Fossati; G Giannella; R Masciulli; M Fagioli; D Bulgarini; D Habetswallner; G Isacchi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Expression of novel interleukin 2 binding molecules and their functional roles in human B cell differentiation.

Authors:  T Tanaka; O Saiki; S Doi; M Suemura; S Negoro; S Kishimoto
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

Review 9.  Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.

Authors:  A Kinter; A S Fauci
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

10.  Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.

Authors:  A von Rohr; A K Ghosh; N Thatcher; P L Stern
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.